ROCKET-AF With Rivaroxaban Enrolls High-Risk Patients

Patients with atrial fibrillation enrolled in the ROCKET-AF trial--looking at whether the novel anticoagulant rivaroxaban is better than warfarin for preventing stroke--are at higher risk of stroke than those who have participated in other recent trials of novel agents for this indication. Heartwire

More on Sciencestage.com

    More on Wikipedia

      Related Videos

      • ROCKET AF (Part II): Video Interview with Jonathan Halperin, MD, FAHA
        ROCKET AF (Part II): Video Interview with Jonathan Halperin, MD, FAHA Science News video interview from Scientific Sessions 2010. Trial: ROCKET-AF - Stroke Prevention Using the Oral Direct Factor Xa inhibitor Rivaroxaban Compar... From: AHAScienceNews Views: 1013 3 ratings Time: 03:33 More in Science & Technology
      • ROCKET AF (Part I): Video Interview with Manesh Patel
        ROCKET AF (Part I): Video Interview with Manesh Patel Science News video interview from Scientific Sessions2010 Trial: ROCKET AF - Stroke Prevention Using the Oral Direct Factor Xa inhibitor Rivaroxaban Compared... From: AHAScienceNews Views: 1644 2 ratings Time: 03:16 More in Science & Technology

      More on answers.yahoo.com

        More on Pubmed

          More on Answers.com